Clinical Trial Update: Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating golimumab in rheumatoid arthritis patients with inadequate response to etanercept or adalimumab; results have been posted (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)
• Humira (adalimumab)
• Simponi (golimumab)

Snippet

Sponsor: Janssen Biotech, Inc. | Conditions: Arthritis, Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2014-05-13